Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

The BiovaxID Phase 3 clinical trial is being conducted at fourteen U.S. oncology centers and 8 centers in Russia.

Applications for accelerated conditional approval of BiovaxID are planned to be submitted to both the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by mid-2008. The DMC has agreed to serve as a liaison between the Company and the FDA and the EMEA. If conditionally approved, BiovaxID could become commercially available in early 2009.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Biovest International, Inc.

Biovest International, Inc., is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. For further information, visit the Company Web site at www.biovest.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company"
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:10/25/2014)... ARBOR, Mich. , Oct. 24, 2014 Advanced ... second quarter (ending September 26, 2014) financial results on Monday, ... will be released after the close of the market and ... discuss the results at 4:30 p.m. EDT on the same ... Richard Kurtz (CEO and Director), Rob Risser ...
(Date:10/25/2014)... , Oct. 24, 2014  The National ... the latest results achieved by Kentucky,s ... The National Precursor Log Exchange ... the point of sale and helps flag meth ... agents often set up NPLEx "watch lists" that ...
(Date:10/25/2014)... DUBLIN , October 24, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/wdq92g/global_and ) has announced the addition ... Industry Report 2014"  report to their ... ,The Global and Chinese Acne Medication Industry ... study on the current state of the ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 Second Quarter Earnings 2Kentucky's NPLEx Technology Making Significant Progress 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3
... SphygmoCor system plays key role in discovery, ... A,new study of more than 10,000 patients, conducted ... United Kingdom using AtCor Medical Holdings,Limited,s SphygmoCor(R) has ... as having "high normal" systolic blood pressure through,traditional ...
... 28 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... oral and,poster presentations on its Cobalamin(TM) technology ... to Clinical Practice, taking,place from May 26-28 ... B12-Polymer Conjugates as Constructs for Targeted Tumor ...
Cached Medicine Technology:New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 2New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 3Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 2Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 3
(Date:10/22/2014)... Grants Pass, OR (PRWEB) October 22, 2014 ... while Southern California’s fresh water supply runs dangerously low, ... climate change. Southern Oregon’s rivers, despite the lowest mountain ... fast even in late summer and early autumn.* That ... Urness, authors of the new book “Hiking Southern Oregon,” ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that ... trouble finding time within their busy schedules for exercise and fitness. ... time to get in shape. Here are five ways you can ... , Change Up Your Commute , Consider riding a bike or ... into your daily routine. If you must use your car to ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... for health services were meant to motivate health care workers ... in Healthcare. According to researchers, these // ... keep manipulation tactics at bay. ,Gwyn Bevan and ... lauded the target based assessment, but have gone further to ...
... of breast cancer or those who suspect it, feel awkward to ... // ,The Prof says that in the UK alone, the ... and nearly 70 succumb to it. This is also because nearly ... to an irrevocable stage. ,Men should watch out for a ...
... International Journal of Cancer on February 17, 2006 tries to ... the level of physical activity in women. // The prospective ... link. ,Experts felt that since exercise is known ... the gastrointestinal transit time, it might also play a constructive ...
... to reduce smoking amongst children have been lauded with a ... an added thrust to the campaign.// Smoking hampers their ... the drive, by augmenting the anti-smoking budget, Hawaii has regressed ... cigarettes have not been hiked, unfortunately, which might have deterred ...
... Research seems to compliment Acupressure over physical therapy, to ... Taiwan University // have acclaimed Acupressure’s success with statistics ... to physical therapy with the effect lasting up to ... pain were treated with six sessions of acupressure, and ...
... to curb the spread of AIDS/HIV, which is haunting the ... authorities from over 20 different countries in the Asia Pacific ... a universal access to AIDS/HIV treatment and prevention would be ... the failure of the WHO target to expand AIDS treatment ...
Cached Medicine News:Health News:Women, Exercise and Colon Cancer 2
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... USS Sports Medicine POLYSORB Meniscal Stapler XLS ... two resorbable legs of the staple. The ... tissue, specifically the meniscus. The staple is ... derivative of lactic acid and glycolic acids. ...
Medicine Products: